Literature DB >> 24847

Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).

A J Claflin, D L Vesely, J L Hudson, C B Bagwell, D C Lehotay, T M Lo, M A Fletcher, N L Block, G S Levey.   

Abstract

We have recently described the presence of a guanylate cyclase [GTP pyrophosphate-lyase (cyclizing), EC 4.6.1.2] inhibitor (GCI) in an aqueous extract of the balsam pear (Momordica charantia abbreviata). Because the guanylate cyclase-cyclic GMP system is though to be involved in cell growth, DNA and RNA synthesis, and possible malignant transformation, we examined the effect of the aqueous extract containing GCI on an undifferentiated adenocarcinoma of the rat prostate and concanavalin-A-stimulated [3H]thymidine incorporation into cultured splenic lymphocytes, a process thought to be mediated by cyclic GMP. The results demonstrate that the extract of the balsam pear blocks both the growth of the rat prostatic adencarcinoma in vitro and [3H]thymidine incorporation into DNA. DNA histograms from flow cytometry indicated that the extract containing GCI inhibited in the G2 + M phase of the cell cycle, a presumed locus of cyclic GMP effects. In addition, guanylate cyclase activity was significantly greater in the tumor than normal prostate tissue and was decreased by the extract containing GCI. Cyclic GMP levels in the tumor in culture wer also decreased by addition of the extract. It remains to be determined whether or not the anti-tumor agent and GCI are the same substance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 24847      PMCID: PMC411385          DOI: 10.1073/pnas.75.2.989

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Guanylate cyclase activity in fetal, neonatal and adult rat heart.

Authors:  D L Vesely; J Chown; G S Levey
Journal:  J Mol Cell Cardiol       Date:  1976-11       Impact factor: 5.000

2.  Hydrazine activation of guanylate cyclase: potential application to tobacco carcinogenesis.

Authors:  D L Vesely; G S Levey
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

3.  Enhancement of human guanylate cyclase activity by chemical carcinogens.

Authors:  D L Vesely; G S Levey
Journal:  Proc Soc Exp Biol Med       Date:  1977-07

4.  PROSTATE CANCER IN THE RAT.

Authors:  W F DUNNING
Journal:  Natl Cancer Inst Monogr       Date:  1963-10

5.  A simple ultrasensitive method for the assay of cyclic AMP and cyclic GMP in tissues.

Authors:  E K Frandsen; G Krishna
Journal:  Life Sci       Date:  1976-03-01       Impact factor: 5.037

6.  Cyclic guanosine monophosphate and cellular growth.

Authors:  Z Miller; E Lovelace; M Gallo; I Pastan
Journal:  Science       Date:  1975-12-19       Impact factor: 47.728

7.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

8.  The content and metabolism of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate in adenocarcinoma of the human colon.

Authors:  F R DeRubertis; R Chayoth; J B Field
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

9.  Activation of guanylate cyclase by streptozotocin and 1-methyl-1-nitrosourea.

Authors:  D L Vesely; L E Rovere; G S Levey
Journal:  Cancer Res       Date:  1977-01       Impact factor: 12.701

10.  Decreased rat hepatic guanylate cyclase activity in streptozotocin-induced diabetes mellitus.

Authors:  D L Vesely; A Castro; G S Levey
Journal:  Diabetes       Date:  1977-04       Impact factor: 9.461

View more
  9 in total

1.  Purified Clostridium difficile cytotoxin stimulates guanylate cyclase activity and inhibits adenylate cyclase activity.

Authors:  D L Vesely; K D Straub; C M Nolan; R D Rolfe; S M Finegold; T P Monson
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

2.  Effect of α, β momorcharin on viability, caspase activity, cytochrome c release and on cytosolic calcium levels in different cancer cell lines.

Authors:  Gunasekar Manoharan; Seema R Jaiswal; Jaipaul Singh
Journal:  Mol Cell Biochem       Date:  2013-12-03       Impact factor: 3.396

Review 3.  Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.

Authors:  Komal Raina; Dileep Kumar; Rajesh Agarwal
Journal:  Semin Cancer Biol       Date:  2016-07-21       Impact factor: 15.707

4.  Testosterone and its precursors and metabolites enhance guanylate cyclase activity.

Authors:  D L Vesely
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

5.  Antileukemic Potential of Momordica charantia Seed Extracts on Human Myeloid Leukemic HL60 Cells.

Authors:  Ramani Soundararajan; Punit Prabha; Umesh Rai; Aparna Dixit
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-13       Impact factor: 2.629

6.  Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells.

Authors:  Ranganatha R Somasagara; Gagan Deep; Sangeeta Shrotriya; Manisha Patel; Chapla Agarwal; Rajesh Agarwal
Journal:  Int J Oncol       Date:  2015-02-09       Impact factor: 5.650

Review 7.  Recent Advances in Momordica charantia: Functional Components and Biological Activities.

Authors:  Shuo Jia; Mingyue Shen; Fan Zhang; Jianhua Xie
Journal:  Int J Mol Sci       Date:  2017-11-28       Impact factor: 5.923

8.  Epidemiologic survey on lung cancer with respect to cigarette smoking and plant diet.

Authors:  R Sakai
Journal:  Jpn J Cancer Res       Date:  1989-06

Review 9.  Bitter Melon (Momordica Charantia), a Nutraceutical Approach for Cancer Prevention and Therapy.

Authors:  Subhayan Sur; Ratna B Ray
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.